Recycled content triacetin (r-triacetin) is produced using a process and system that applies physical and/or credit-based recycled content from one or more feed materials to triacetin produced from the feed materials.

Recycled content triacetin (r-triacetin) is produced using a process and system that applies physical and/or credit-based recycled content from one or more feed materials to triacetin produced from the feed materials.

In accordance with the present subject matter there is provided a process for producing mono-, di- and triesters of glycerol over a catalyst composition. The catalyst composition including a base catalyst and a support material based on phyllosilicates of montmorillonite structure and the process for preparing the catalyst composition is also described.

In accordance with the present subject matter there is provided a process for producing mono-, di- and triesters of glycerol over a catalyst composition. The catalyst composition including a base catalyst and a support material based on phyllosilicates of montmorillonite structure and the process for preparing the catalyst composition is also described.

A novel fragrance carrier comprising 1,2,3-triacetoxypropane (triacetin) of formula I:

##STR00001##

A novel fragrance carrier comprising 1,2,3-triacetoxypropane (triacetin) of formula I:

##STR00001##

A method of treating a leukemia comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising a compound of Formula (I) and/or (II) having the structure: OR2 R R1O n OR2 R R1O n I II wherein: 10 ---- represents a single or a double bond; R is OH when C----R is C—R, and R is O when C----R is C═R; n is 1, 3, 5 or 7; and R1 and R2 are independently hydrogen or acetyl, and/or isomers, stereoisomers or solvates thereof and/or mixtures thereof.

##STR00001##

The present invention relates to a group of derivatives synthesized based on the ent-kaurane diterpenoid flexicaulin A and the methods to synthesize such diterpenoid derivatives. In particular, the chemical entities of such synthetic diterpene compounds in the manufacture of a medicament is for the treatment of tumors or cancers.

The present invention relates to an enzymatic synthesis of 4′-ethynyl-2′-deoxy nucleosides and analogs thereof, for example EFdA, that eliminates the use of protecting groups on the intermediates, improves the stereoselectivity of glycosylation and reduces the number of process steps needed to make said compounds. It also relates to the novel intermediates employed in the process.

The present invention relates to an enzymatic synthesis of 4′-ethynyl-2′-deoxy nucleosides and analogs thereof, for example EFdA, that eliminates the use of protecting groups on the intermediates, improves the stereoselectivity of glycosylation and reduces the number of process steps needed to make said compounds. It also relates to the novel intermediates employed in the process.